Safety and efficacy outcomes of unmatched and PSM groups
| Outcome | Unmatched groups | PSM groups | ||||
| TNK | Alteplase | P value | TNK | Alteplase | Adj. P value | |
| Primary outcomes | ||||||
| sICH, n/N (%) | 20/1113 (1.8%) | 55/2360 (2.33%) | 0.313 | 20/1113 (1.8%) | 22/1113 (1.98%) | 0.864 |
| Secondary outcomes | ||||||
| Safety outcomes, n/N (%) | ||||||
| Any intracranial bleeding | 23/1113 (2.07%) | 109/2360 (4.62%) | 0.000 | 23/1113 (2.07%) | 45/1113 (4.04%) | 0.012 |
| PH2 | 15/1113 (1.35%) | 41/2360 (1.74%) | 0.396 | 15/1113 (1.35%) | 16/1113 (1.44%) | 0.979 |
| Any systemic bleeding | 5/1113 (0.45%) | 3/2360 (0.13%) | 0.065 | 5/1113 (0.45%) | 2/1113 (0.18%) | 0.379 |
| Mortality at 90 days | 68/1094 (6.22%) | 181/2208 (8.2%) | 0.042 | 68/1094 (6.22%) | 77/1034 (7.45%) | 0.231 |
| Efficacy outcomes | ||||||
| 24-hour NIHSS score* median (IQR) | 2 (1, 5), n=1108 | 3 (1, 7), n=2324 | 0.000 | 2 (1, 5), n=1108 | 3 (1, 7), n=1110 | 0.000 |
| 24-hour NIHSS score improvement ≥4 OR ≤1 | 637/1108 (57.49%) | 953/2324 (41.01%) | 0.000 | 637/1108 (57.49%) | 478/1100 (43.45%) | 0.000 |
| mRS at 90 days, median (IQR)† | 0 (0–2) n=1094 | 1 (0–3) n=2208 | 0.000 | 0 (0–2), n=1094 | 1 (0–3), n=1034 | 0.000 |
| mRS 0–1 at 90 days, n (%) | 788 (72.03%) | 1417 (64.18%) | 0.000 | 788/1094 (72.03%) | 690/1034 (66.73%) | 0.012 |
| mRS 0–2 at 90 days, n (%) | 885 (80.90%) | 1625 (73.6%) | 0.000 | 885/1094 (80.9%) | 773/1034 (74.76%) | 0.001 |
p value in the PSM groups were adjusted for oral anticoagulant use and DNT.
*Quantile regression.
†Ordinal logistic regression.
DNT, door-to-needle time; NIHSS, National Institutes of Health Stroke Scale; PH2, parenchymal haematoma type 2; PSM, propensity score matching; sICH, symptomatic intracranial haemorrhage; TNK, tenecteplase.